The researchers caution, however, that no definitive conclusions can be drawn from this small, retrospective study. “Phase 2, randomized clinical trials are ongoing, which should provide definitive conclusions,” Dr. Cavalli tells Reuters Health.
In a linked comment, Dr. Scott Canna and Dr. Kate Kernan of the University of Pittsburgh Medical Center, say, “In view of the biological plausibility of anakinra, the pharmacokinetic and safety profile of the drug, and a growing body of positive experience in autoinflammation and cytokine storm, these data are promising and support prioritizing this approach in the planning and enrollment of randomized controlled trials.”2
The study had no specific funding and the authors have declared no relevant conflicts of interest.
Reference
- Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020 May 7.
- Kernan KF, Canna SW. Should COVID-19 take advice from rheumatologists? Lancet Rheumatol. 2020 May 7.
